September 2022

Contents

Editorial

HTB September 2022 (1 September 2022)

Special reports

Update on monkeypox in the UK: reduced cases, vaccine access, transmission and treatment…

Conference reports

24th International AIDS Conference (AIDS 2022)

Dolutegravir no longer linked to higher risk of neural tube defects: latest update from the Tsepamo study

Weight gain with dolutegravir and TAF in ADVANCE study continues out to week 192

VRC01 added to early ART in infants did not reduce viral reservoir

Using PrEP during pregnancy is safe for children

Long-acting CAB/RPV injections have a similar weight and lipid profile to dolutegravir-based oral ART

Montreal’s response to monkeypox: rapid vaccine rollout, 39 breakthrough infections

Summary of 620 cases of monkeypox seen at three London clinics

Advances in HIV cure-related research: IAS workshop now online

Antiretrovirals

Lenacapavir approved in the EU and UK to treat multidrug resistant HIV

mpox

US survey reports 50% of gay men changed sexual behaviour to avoid monkeypox

US model limits monkeypox infections by one-third from having fewer one-time partners: short-term strategy until next vaccine supply

BHIVA include efficacy data on HIV and monkeypox vaccine: updated statement (August 2022)

Monkeypox DNA detected in anal samples of asymptomatic men in Paris and Belgium

Unusual case reports: non-sexual acquisition, severe MPX and advanced HIV, human-to-dog transmission

Tecovirimat for treating mild monkeypox: new studies open in the UK and US

US cases: MMWR report on 1891 cases to 22 July 2022

Monkeypox transmission in heterosexual couples in Nigeria

Access to vaccines and treatment for pregnant women at risk of monkeypox

MPX DNA easily detected on surfaces in hospital after cleaning

Understanding HIV and monkeypox coinfection: NEAT/EACS dashboard

HIV prevention and transmission

HIV seroconversions on PrEP in Australian study are linked to low adherence

PDFs

HTB: no. 9 (3 September 2022) PDF download